Kuros Biosciences AG (SWX:KURN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 853.74M -18.9% |
| Revenue (ttm) | 141.35M +42.5% |
| Net Income | 7.25M |
| EPS | 0.18 |
| Shares Out | 39.67M |
| PE Ratio | 123.20 |
| Forward PE | 79.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,789 |
| Open | 21.42 |
| Previous Close | 21.52 |
| Day's Range | 20.80 - 21.46 |
| 52-Week Range | 17.69 - 34.20 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 33.92 (+61.22%) |
| Earnings Date | Aug 13, 2026 |
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone graft... [Read more]
Analyst Summary
According to 4 analysts, the average rating for KURN stock is "Strong Buy." The 12-month stock price target is CHF 33.92, which is an increase of 61.22% from the latest price.
News
Kuros Biosciences AG Earnings Call Transcript: Q2 2026
Revenue grew 45% year-over-year to $92.4 million, with adjusted EBITDA of $12.5 million and net profit of $4.4 million, marking a shift to profitability. Growth is driven by strong U.S. adoption, expanding clinical evidence, and operational scaling, with margin improvement expected as new manufacturing comes online.
Kuros Biosciences AG Quarterly report: Q2 2026
Kuros Biosciences AG has published its Q2 2026 quarterly earnings report on August 13, 2026.
Kuros Biosciences AG Earnings release: Q2 2026
Kuros Biosciences AG released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Kuros Biosciences AG Slides: Q2 2026
Kuros Biosciences AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Kuros Biosciences initiated with a Buy at Berenberg
Berenberg initiated coverage of Kuros Biosciences (CSBTF) with a Buy rating and CHF 32 price target Kuros Biosciences is a fast-growing, commercial-stage med-tech “pioneer” transforming the global bon...
Kuros Biosciences AG Transcript: CMD 2026
Profitability and rapid revenue growth have been achieved through strategic expansion into new markets, robust clinical evidence, and operational transformation. MagnetOs continues to gain market share, supported by ongoing level 1 studies and product innovation, while financial guidance and margin targets remain on track.
Kuros Biosciences AG Press release: FY 2026
Kuros Biosciences AG issued a press release on June 17, 2026, disclosing material business information to investors.
Kuros Biosciences AG Slides: FY 2026
Kuros Biosciences AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 17, 2026.
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product ...
Kuros Biosciences AG Earnings release: Q1 2026
Kuros Biosciences AG released its Q1 2026 earnings on April 14, 2026, summarizing the period's financial results.
Kuros Biosciences AG Earnings Call Transcript: H2 2025
Achieved first-time profitability in 2025 with 72% revenue growth and strong operational execution. Guidance for 2026 targets at least 35% revenue growth and 14% adjusted EBITDA margin, with continued expansion in spine, extremities, and trauma segments.
Kuros Biosciences AG Earnings release: H2 2025
Kuros Biosciences AG released its H2 2025 earnings on March 10, 2026, summarizing the period's financial results.
Kuros Biosciences AG Annual report: H2 2025
Kuros Biosciences AG has published its H2 2025 annual report on March 10, 2026.
Kuros Biosciences AG Slides: H2 2025
Kuros Biosciences AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 10, 2026.
Kuros Biosciences AG Earnings release: Q3 2025
Kuros Biosciences AG released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.